Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms

CompletedOBSERVATIONAL
Enrollment

397

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Myeloproliferative Neoplasm
Interventions
BIOLOGICAL

2 additional tubes of blood

2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation

Trial Locations (24)

Unknown

CHU Angers, Angers

CH Annecy Genevois, Annecy

CH Avignon, Avignon

CHU Bordeaux, Hématologie Biologique, Bordeaux

CHU Bordeaux, Hématologie Clinique et Thérapie Cellulaire, Bordeaux

CHU Bordeaux, Médecine Interne, Bordeaux

Institut Bergonié, Bordeaux

CHRU Brest, Brest

CHU Henri Mondor - APHP, Créteil

CH Dax, Dax

CHU Dijon, Dijon

CHU Limoges, Limoges

Centre Léon Bérard, Lyon

CH Mont de Marsan, Mont-de-Marsan

CHU Nancy, Nancy

Hôpital Européen Georges Pompidou - APHP, Paris

Hôpital Saint-Louis - APHP, Paris

CH Perpignan, Perpignan

CHU Poitiers, Poitiers

CH Rochefort, Rochefort

CH Roubaix, Roubaix

IUCT-Oncopôle, Toulouse

CH Valenciennes, Valenciennes

Hôpital Paul Brousse, Villejuif

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT04177576 - Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter